Table 1 Clinicopathological characteristics of patients
Variables | n = 141 (%) |
|---|---|
Age (y.o. mean ± SD) | 52.3 ± 10.1 |
Sex (Male/Female) | 0/141 |
Menopausal status | |
 Premenopausal | 79 (56.0) |
 Postmenopausal | 62 (44.0) |
Histological type | |
 Invasive ductal carcinoma | 127 (90.1) |
 Special type | 14 (9.9) |
Histological grade | |
 1 | 38 (27.0) |
 2 | 69 (48.9) |
 3 | 29 (20.6) |
 Undetermined | 5 (3.5) |
Subtype | |
 Luminal | 75 (53.2) |
 Luminal HER2 | 30 (21.3) |
 HER2-enriched | 16 (11.3) |
 Triple negative | 20 (14.2) |
Lymph node metastasis | |
 Positive | 122 (86.5) |
 Negative | 19 (13.5) |
Pre-NAC clinical stage | |
 II | 89 (63.1) |
 III | 52 (36.9) |
Regimens of NAC | |
 EC/FEC → PTX and/or TRA | 57 (40.4) |
 EC/FEC → DTX and/or TRA | 84 (59.6) |
Surgical procedures | |
 Mastectomy + Axillary dissection | 107 (75.9) |
 Partial resection of breast + Axillary dissection | 34 (24.1) |
Pathological response to NAC | |
 Non-pCR | 112 (79.4) |
 pCR | 29 (20.6) |
SMI (mean ± SD) | |
 Pre-NAC | 46.5 ± 7.6 |
 Post-NAC | 46.3 ± 8.0 |
BMI (mean ± SD) | |
 Pre-NAC | 22.4 ± 3.7 |
 Post-NAC | 22.4 ± 3.7 |
Percent change in SMI | −27.7 to 19.6 |
Percent change in BMI | −22.9 to 34.2 |
Alb (g/dl; mean ± SD) | |
 Pre-NAC | 4.50 ± 0.30 |
 Post-NAC | 4.07 ± 0.36 |
NLR (mean ± SD) | |
 Pre-NAC | 2.53 ± 1.54 |
 Post-NAC | 3.03 ± 1.61 |
Change in Alb | −1.1 to 0.6 |
Change in NLR | −5.20 to 6.00 |
Recurrence | |
Total | 33 (23.4) |
 Locoregional (Chest wall, ScLN, PsLN) | 5 (3.5) |
 Distant (Bone, lung, liver, brain) | 28 (19.9) |